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Abstract:  Rheumatoid  arthritis  is  a  common  chronic  inflammatory  and
destructive  arthropathy  that  consumes  considerable  personal,  social  and
economic costs. It consists of a syndrome of pain, stiffness and symmetrical
inflammation  of  the  synovial  membrane  (synovitis)  of  freely  moveable
joints  such  as  the  knee  (diarthrodial  joints).  Although  the  etiology  of
rheumatoid arthritis is unclear, the disease is characterized by inflammation
of the synovial lining of diarthrodial joints, high synovial proliferation and
an  influx  of  inflammatory  cells,  macrophages  and  lymphocytes  through
angiogenic  blood  vessels.  Disease-modifying  antirheumatic  drugs  slow
disease  progression  and  can  induce  disease  remission  in  some  patients.
Methotrexate is the first line therapy, but if patients become intolerant to
this drug, biologic agents should be used. The development of biological
substances for the treatment of rheumatic conditions has been accompanied
by ongoing health economic discussions regarding the implementation of
these highly effective, but accordingly, highly priced drugs are the standard
treatment  guidelines  of  rheumatic  diseases.  In  this  way,  more  efficient
strategies have to be identified. Despite numerous reviews in rheumatoid
arthritis in the last years, this area is in constant development and updates
are  an  urgent  need  to  incorporate  new  advances  in  rheumatoid  arthritis
research. This review highlights the immunopathogenesis rationale for the
current therapeutic strategies in rheumatoid arthritis.
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INTRODUCTION
Rheumatoid arthritis (RA) is the most common
form  of  chronic  inflammatory  arthritis,  characte-
rized  by  inflammation  of  the  joints,  resulting  in
synovial  hyperplasia  by  infiltration  of  activated
immune cells leading to further cartilage and bone
destruction  [1].  In  1500  BC,  Ebers  Papyruralies
described a condition similar to RA. Several reports
have suggested over time that  Egyptian mummies
were found to have deformities similar to arthritis,
however only in 1800 this condition was named RA
by  Garrod,  replacing  the  old  terms  arthritis
deformans  and  rheumatic  gout  [2].
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RA  occurs  worldwide  although  the  estimated
prevalence  ranges  from  around  1%  of  the  adult
population in northern Europe and USA to around
0.5%  in  other  geographic  areas.  This  disease  is
clearly  commonest  in  women  than  in  men  with  a
ratio of approximately 3:1 [3]. RA can develop in
persons of any age, with a typical onset age of 55
years [4]. Mortality rates in RA are higher than in
the  general  population  (ranges  from 1.28  to  2.98)
[5].  Life  expectancy  is  shortened  by  up  to  3  to  5
years, especially in patients that develop treatment-
related adverse effects including infections, tumors
and gastrointestinal toxicity from drugs used in RA
therapy  [4,  6].  Furthermore,  it  is  known  that
patients  with  RA  are  at  increased  risk  for  acute
cardiovascular events, compared with the rest of the
population [7]. In this way, the commonest cause of
death in RA is cardiovascular diseases, accounting
for more than 50 % of the mortality [1].
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Genetic Factors and Environmental Pressure
As many other diseases, RA is a combination of
genetic  and  environmental  factors  that  when
present,  increase  the  susceptibility  to  develop
clinical  manifestations [2].  Several  loci  contribute
to  the  genetic  risk  for  RA,  with  the  human
leukocyte  antigen  (HLA)  locus  being  the  most
significant,  and  accounting  for  30%  to  50%  of
overall  genetic  susceptibility  to  RA  [8].  HLA
molecules are essential for antigen presentation in
the  immune  response.  Although  the  association
between  HLA  and  RA  is  not  fully  understood,  it
appears  that  antigen  presentation  and  the  type  of
immune  activation  that  leads  to  (auto)antibody
formation are important in RA [9]. Other locus with
strong  association  are  described  in  Table  1,
highlighting a polymorphism in the protein tyrosine
phosphatase nonreceptor 22 (PTPN22) gene, which
encodes  the  protein  tyrosine  phosphatase  [8].
Recent  genome-wide  association  studies  (GWAS)
meta-analysis  discovered  novel  RA  risk  loci  with
significant at a genome-wide level of significance,
accounting  for  101  [10,  11].  However,  these  risk
loci do not fully explain the genetic contribution to
disease susceptibility, and common genetic variants
do not have equal causative effects [12, 13].
Several  environmental  factors  have  been
associated in the development of RA, however not
all  are  consensual.  It  is  believed  that  early  life
factors,  such  as  higher  birth  weight  or  maternal
smoking, may be important in developing the risk
of  RA.  Tobacco  smoking  is  the  environmental
factor  remarkably  most  associated  with  a  higher
risk  of  RA  [3].  A  study  revealed  that  smoking
history of more than40 pack-years increases 2-fold
the  risk  of  RA  (compared  to  nonsmokers),
persisting  even  after  smoking  cessation  [15].
However, this higher risk of RA is just presented in
patients  with  seropositive  RA  (rheumatoid  factor,
RF, positive) and, especially, patients with positive
anti-citrullinated  peptide/  protein  antibodies
(ACPA) [3]. Other bronchial stressors such as silica
are  also  defined  as  risk  factors  for  severe  RA.
Furthermore,  infectious  agents,  such  as
Porphyromonas  gingivalis  associated  with
periodontal  disease,  are  also  linked  to  RA  as
environmental  factors  [15].
Table 1. Genetic susceptibility to RA [8, 14].
Gene/locus Odds ratio Function Relevant to Pathogenesis
HLA-DRB1 SE alleles Single SE ~3 to
4.5; double SE
~7 to ~13
HLA DRB1 allele involved in MHC molecule–based antigen presentation and accountable
for self-peptide selection and T-cell repertoire
PTPN22 Arg620→Trp ~1.6 Lymphocyte-specific nonreceptor tyrosine phosphatase imlivated in regulation of
activation threshold of lymphocytes
STAT4 ~1.3 Transducer of cytokine signals that control proliferation, survival, and differentiation of
lymphocytes
TNFAIP3 ~1.2 Signaling protein and negative regulator of TNF-α–induced NF-κB activation
TRAF1/C5 ~1.3 Regulator of TNF-α–receptor superfamily signaling (e.g., to NF-κB and JNK)
SE: shared epitope; STAT: signal transducer and activator of transcription; TNFAIP3: tumor necrosis factor alpha induced protein
3; TRAF1/C5: tumor necrosis factor–associated factor 1 and complement component C5;  MHC: major histocompatability complex;
TNF: tumor-necrosis factor; NF-κB: factor nuclear kappa B; JNK: Janus N-terminal kinase
Classification Criteria
The  classification  criteria  of  RA  proposed  by
the American College of Rheumatology (ACR) in
1987  differentiated  established  RA  from  other
rheumatic  disorders  [16],  but  it  is  not  precise  for
early  disease  stages.  Indeed,  the  classification
criteria were based on patients in whom the average
disease duration was 7 years and were consequently
highly specific for established RA [17]. Four of the
seven next criteria must be present, and criteria 1-4
must  have  been  present  for  at  least  6  weeks:
morning stiffness (≥ 1 hr); arthritis of three or more
joints  areas;  arthritis  of  hand  joints  (>  1  swollen
joint);  symmetric  arthritis;  rheumatoid  nodule;
serum  RF;  radiographic  changes  (erosions).
Actually,  it  is  known  that  there  is  a  period  of
development  of  RA  that  is  characterized  by
abnormalities  of  autoantibodies  and  other
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biomarkers  in  the  absence  of  clinically  apparent
inflammatory  arthritis  that  characterizes  RA [18].
The  first  RA-associated  antibody,  RF,  was
discovered in 1940, and it was posteriorly found to
be  directed  to  the  crystallizable  fragment  (Fc)
region of  imunoglobulina (Ig)G.  More recently,  it
has  been shown that  the autoantibodies  present  in
RA  are  antibodies  directed  against  proteins
containing citrulline epitopes. These antibodies are
called  ACPA  and  can  recognise  the  non-classical
amino acid citrulline, present on a protein sequence.
Citrulline  is  produced  by  a  post-translational
modification of arginine mediated by an enzymatic
process.  This  reaction  occurs  during  a  variety  of
biological processes, including inflammation [9]. In
fact,  there  are  commercially  available  anti-cyclic
Citrullinated  Peptide  (CCP)  ELISA  assays,  based
on  artificial  CCP,  of  which  several  generations
exist  (e.g..,  CCP2,  CCP3)  [18].
New criteria for the classification/ diagnosis of
RA  were  therefore  proposed  in  2010  by  experts
from  both  ACR  and  European  League  Against
Rheumatism  (EULAR)  [19].  The  most  common
clinical manifestations of RA are gradual onset of
polyarthralgia  with  symmetrical,  intermittent  and
migratory joint involvement, especially in the hands
and  feet.  It  is  important  to  note  that,  due  to  its
clinical importance, feet involvement was included
in the ACR/EULAR 2010 classification, despite the
fact that their involvement was not part of some of
the  activity  index.  Symmetrical  inflammation  of
small  and  large  articulations  accompanied  by
morning  stiffness  is  also  a  common  symptom  of
RA [2].
The new criteria consider a probabilistic method
to RA diagnosis and are particularly useful before
the  erosions  that  are  typical  when  RA is  detected
(Fig. 1). They include four scored areas: symptom
duration  (<  or  >6  weeks),  number  and  site  of
involved joints, biomarkers of inflammation (acute-
phase  response),  and  biomarkers  of  specific
autoimmunity  (RF  and  ACPA).
Fig. (1). Classification criteria of RA on earlier stages.
Only patients with at least 6 in 10 points,  may
be classified as having RA. Obviously, the criteria
do not apply if patients already have joint erosions
that are visible on standard X-rays [17]. In addition
to  identifying  individuals  at  high  risk  for  chronic
disease activity and erosive damage, these criteria
would also be used as a base for selecting patients
who  require  targeted  treatment  early  in  disease
progress  [20].
It  is  possible  to  define  three  phases  in  RA
pathogenesis.  In  the  first  phase,  autoimmunity
develops  in  healthy  but  genetic-susceptible
individuals, wh0 have not experienced any clinical
manifestation. The second phase refers to the time
immediately  before  to  or  the  clinical  start  for
diagnosis  of  RA.  This  stage  has  been  difficult  to
study in man,  despite several  efforts  made for the
detection of first signs and symptoms of disease. In
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the  third  phase,  inflammation  is  converted  into  a
chronic  and  destructive  process.  At  this  stage  the
patients meet the classification criteria of RA, and
they  become  the  target  of  therapeutic  approaches
[21].
Immunopathogenesis
Being an autoimmune disease, RA patients have
a  problem  in  distinguishing  between  self  and
foreign  molecules.  Humoral  and  cellular  immune
responses  to  autoantigens,  like  the  production  of
RFs,  occur  in  RA  [1].  Although  the  cause  of  RA
remains unclear,  it  is  known that  the immune and
inflammatory  systems  are  closely  related  to  the
destruction of cartilage and bone [22]. Indeed, the
complex  interaction  of  immune  modulators
(cytokines and effector cells) leads to joint damage
that  begins  at  the  synovial  membrane  and  affects
most RA structures (Fig. 2). The influx and/or local
activation of mononuclear cells  (including macro-
phages and T, B, plasma, dendritic and mast cells)
and  the  formation  of  new  blood  vessels  are
characteristic  of  synovitis  [23].
Fig. (2). Schematic view of a (a) normal joint and (b) a joint affected by RA.  The ‘radiographic joint space’ of
metacarpophalangeal joints in (c) a normal hand and (d) from a patient with established RA (Adapted from Nogueira et
al., 2016 [33]).
T Cells
CD4+  helper  T  (Th)  cells  make  a  crucial
contribution  to  the  development  of  inflammatory
arthritis,  where two T-cell  subsets  have been well
characterized.  T  cells  undergo  polarization  into
either  Th1  or  Th2  cells,  which  is  mutually
exclusive.  Th1  cells  have  pro-inflammatory
potential  and  promote  certain  humoral  responses,
whereas  Th2  cells  exert  anti-inflammatory  effects
[22]. RA is clearly characterized by a change in the
direction of  the pro-inflammatory Th1 phenotype,
with  overproduction  of  interferon  (IFN)γ  and
unsuited  production  of  Th2  cytokines  like
interleukin  (IL)-4  and  IL-13.
The model  attributing a  key role  to  a  Th1/Th2
imbalance in RA was clarified by the identification
of  Th17  and  T-regulatory  (Treg)  lymphocyte
subsets  [24].  Th17  cells  produce  the  proinflam-
matory cytokine IL-17,  which acts  on several  cell
types  found  in  rheumatoid  joints:  monocytes,
macrophages,  fibroblasts,  osteoclasts  and  chond-
rocytes.  Furthermore,  this  cytokine also induces a
wide range of effector molecules implicated in joint
damage  [8].  The  immune  response  needs  to  be
controlled to avoid chronic inflammation. For this
purpose,  Treg  cells,  known  to  have  suppressor
activity,  are  pivotal  in  the  maintenance  of  self-
tolerance  [25].  Although  Treg  cells  can  regulate
any Th subset,  special attention has been given to
the Th17/Treg balance [26].
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Th22  subset  is  a  more  recently  identified  Th
subset, which is characterized by secretion of IL-22
but  not  IL-17  or  IFN-γ  [27].  IL-22,  a  member  of
IL-10  cytokine  family,  has  been  believed  as  an
important  player  in  regulating  inflammatory
responses  associated  with  many  inflammatory
diseases [28]. It was demonstrated that the number
of  Th22  cells  significantly  increased  in  the
peripheral  blood  of  patients  with  RA  compared
with  healthy  controls  [28,  29].  However,  recent
results  indicate  that  Th22  cells  are  less  potent  in
inducing synovial inflammation compared to Th17
cells [30].
Although  its  role  is  not  fully  understood,  Th9
are also overexpressed in RA synovial tissue [31].
This cell subset, characterized by the production of
IL-9,  is  increased  in  RA  and  is  specifically
activated  by  citrullinated  peptides  [32].
B Cells
B  cells  play  several  key  roles  in  the
pathogenesis of RA. Their primary function is the
production  of  autoantibodies,  RF  and  ACPA,
resulting  in  a  large  immunecomplex.  Through
complement  and  Fc-receptor  activation,  this
structure  can  stimulate  the  production  of  pro-
inflammatory  cytokines,  such  as  TNF-α  [1,  23].
Furthermore,  B  cells  with  specificity  for  self-
immunoglobulin  can  bind  and  internalize
immunoglobulin– antigen complexes and enhance
antigen-presenting function by generating a  wider
range  of  peptides  [34].  In  this  way,  besides  the
production of autoantibodies and pro-inflammatory
cytokines,  B  cells  can  also  present  antigens  to  T
cells  and  supply  costimulatory  signals  which  are
crucial  for  T cell  activation,  clonal  expansion and
effector functions [35].
Synovial Fibroblasts
There  is  growing  evidence  that  activated
synovial  fibroblasts  (SFs),  largely  present  in
rheumatoid synovium, are one of the main players
in  the  destructive  process  of  RA  [36].  Once  acti-
vated, SFs produce increased amount of cytokines,
chemokines  and  matrix-degrading  enzymes  that
inhibit  the contact  with neighboring inflammatory
and endothelial cells, which leads to destruction of
articular  cartilage  and  bone  [37].  In  this  way,  the
production  of  cytokines  and  chemokines  helps  to
recruit macrophages, neutrophils and T cells or the
rheumatoid  synovium,  which  attract  more  inflam-
matory  cells  and,  which,  in  turn,  increase  the
activated  state  of  the  SFs  and  of  osteoclasts  [1].
Osteoclasts
Osteoclasts are the prime bone resorbing cells,
vital  for  the  remodeling  of  bone  throughout  life.
These multinucleated cells of hematopoietic origin
have  two  key  molecular  machineries,  essential  to
their bone resorb function [38]. Osteoclasts utilize a
proton pump to acidify the environment deep to the
ruffled border and solubilize mineral from bone. In
addition,  proteolytic  enzymes  including  matrix
metalloproteinases  (MMPs)  and  cathepsin  K  are
secreted that degrade the organic bone matrix [39].
Chondrocytes
Chondrocytes are a cell population exclusive of
adult  human  articular  cartilage,  which  covers  the
articulating  surfaces  of  long  bones.  Under
physiological  conditions,  the  chondrocytes  keep  a
constant  balance  between  the  synthesis  and  the
degradation of matrix components [40]. However,
influenced by synovial cytokines (mainly IL-1 and
IL-17A) and reactive nitrogen species, cartilage is
gradually  deprived  of  chondrocytes,  resulting  in
apoptosis  [14].
Macrophages
Macrophages  are  of  vital  importance  in  the
pathogenesis of RA, due to their higher presence in
the  inflamed  synovial  membrane,  their  activation
status  and  their  successful  reaction  to  anti-
rheumatic therapy [1, 41]. Activated macrophages
display  different  phenotypes  depending  on  the
nature  of  the  recruiting  stimulus  and  the  location
[42]. Activated macrophages may release cytokines
(IL-1,  IL-6,  TNFα),  chemokines  (e.g,  monocyte
chemotactic  protein-1,  MCP-1/CCL2),  digestive
enzymes  (e.g,  collagenases),  prostaglandins,  and
reactive  oxygen  species  (ROS),  responsible  for
damage  of  the  normal  tissues  [43].  Moreover,
activated macrophages contribute to the activation
and proliferation of antigen specific T-cells due to
their participation in antigen presentation [44].
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Current RA Therapy
The  treatment  of  RA  in  the  last  years  is
characterized by a firm evolution of new agents and
new approaches [45]. Progress in knowledge about
cellular and molecular mechanisms of RA and the
development  of  new  therapies  have  altered  the
overview  of  scientific  community  about  RA.
Discoveries concerning its pathogenesis have led to
the  development  of  new  agents  with  specific
molecular  targets,  which  have  changed  the
prognosis  for  numerous  RA  patients.  Treatment
paradigms  in  RA  have  shifted  dramatically  from
controlling  symptoms  (using  nonsteroidal  anti-
inflammatory drugs, NSAIDs, and corticosteroids)
to  controlling  the  disease  course  with  the
suppression  of  inflammation  (disease-modifying
antirheumatic  drugs,  DMARDs,  and  biologics)
[17]. This change in RA management results from
growing  evidences  suggesting  that  early  RA
identification and treatment with DMARDs lead to
improved  prognosis  and  outcomes.  Therefore,  the
aims  of  RA  management,  besides  disease
remission,  also  include  an  improved  functional
status.  This issue can be assessed by radiographic
joint damage, an important analysis for the impact
that the initiation of suitable treatment during early
RA  has  on  these  outcomes  is  essential  [46].  The
present  treatment  objective  in  RA  is  to  reach
permanent,  and  complete  disease  suppression
leading in remission or even cure. Remission stops
damage, prevents disability, increases quality of life
and  lowers  mortality  rates.  Remission  should  be
defined as the absence of disease activity, reflected
as no clinical  sign of synovitis,  the elimination of
smoldering, clinically silent synovial inflammation,
and the control of acute-phase response. However,
even constant “low-grade inflammation” is related
to  the  possibility  of  comorbidities  and  increased
mortality  in  RA  [17].
Pain  relief  is  an  important  achievement  in  RA
therapy, but is only partly achieved by NSAIDs or
opioids drugs, which do not have any influence on
the autoimmune character of the disease. However,
glucocorticoids  and  immunosuppressive  agents,
normally  used  in  combination  to  reduce  pain  and
inflammation  in  short-term,  are  capable  of
achieving  some  clinical  remission.  Over  an
extended  period  of  time,  higher  doses  can  induce
severe  side  effects.  Therefore,  agents  that  possess
the ability to constantly reduce inflammation and,
therefore, maintain joint integrity, with minor side
effects, are preferred for the treatment of RA [47].
DMARDs form two main categories: synthetic
chemical  compounds  (sDMARDs)  and  biological
agents (bDMARDs). Due to the latest development,
a  new  nomenclature  for  DMARDs  has  been
recently proposed [48]. Therefore, the conventional
sDMARDs  (csDMARDs)  will  be  applied  to
chemical  agents  such  as  methotrexate  (MTX),
sulfasalazine and leflunomide. In turn, tofacitinib, a
new sDMARD to target JAKs, will be nominated as
a  targeted  sDMARD  (tsDMARD).  The  TNF
inhibitors  (adalimumab,  certolizumab  pegol,
etanercept,  golimumab and infliximab),  the T cell
costimulation inhibitor (abatacept),  the anti-B cell
agent  (rituximab)  and  the  IL-6  receptor  (IL-6R)-
blocking  monoclonal  antibody  (tocilizumab)  as
well as the IL-1 inhibitor (anakinra) will be termed
as biological originator (bo) DMARDs. Finally, the
biosimilars  (bs)  therapeutic  agents,  such  as  bs-
infliximab,  recently  approved  by  the  European
Medicines  Agency  (EMA),  will  be  designated  as
bsDMARDs [49].
Synthetic DMARDs
Of  the  many  effective  antirheumatic  drugs
available nowadays, DMARDs constitute the basis
of treatment. Currently available DMARDs include
synthetic  or  chemical  drugs  (Table  2),  of  which
EULAR  recommends  three  due  to  their  efficacy
and  safety  profile:  MTX,  leflunomide  and
sulfasalazine [3]. In turn, parenteral gold salts and
antimalarial  agents  (such  as  hydroxychloroquine
and  chloroquine)  are  used  most  commonly  in
combination with other synthetic DMARDs, rarely
as  monotherapy  [3].  Tofacitinib,  a  new  synthetic
DMARD,  is  a  Janus  kinase  (JAK)  inhibitor
blocking  downstream  signaling  for  several
cytokines  integral  to  lymphocyte  function  [50].
Although  it  was  the  first  synthetic  DMARD
approved  by  the  Food  and  Drug  Administration
(FDA)  for  RA  therapy,  as  well  as  regulatory
agencies  in  several  countries,  the  EMA  did  not
approve  this  drug  [51].
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Table 2. Mode of action of synthetic DMARDs therapies used in RA.
Drug Target Function of target and effect
Methotrexate Folate-dependent enzymes (DHFR,
TS, ATIC)
DHFR, TS and ATIC ↓: impaired pyrimidine and purine synthesis
leads to inhibition of lymphocyte proliferation AICAR ↑: high
adenosine levels show anti inflammatory effects
Leflunomide DHODH DHODH ↓: impaired pyrimidine synthesis leads to inhibition of
lymphocyte proliferation
Sulfasalazine Folate-dependent enzymes Unclear mechanism of action; inhibition of folate-dependent enzymes
was observed (see MTX); further described effects are: blockade of
IκB and induction of apoptosis of neutrophils and macrophages
Gold salts Interaction with sulfur-containing
amino acids in plasma or
intracellular proteins
Inhibition of signal transduction and antigen presentation
(Hydroxy)chloroquine Lysosomes, lysosomal enzymes,
TLR-9
Lysomotropic properties hinder antigen presentation Impaired
activation of the innate immune system
Tofacitinib JAK1 and JAK3 (>JAK2 and
TYK)
Leukocyte maturation and activation ↓ Cytokine and immunoglobulin
production ↓
↓: Decrease; ↑: Increase; DHFR: Dihydrofolate reductase; DHODH: Dehydroorotate dehydrogenase; TS: Thymidilate synthase;
IκB: inhibitor of kappa B; TYK: tyrosine-protein kinase
MTX is  the  first  line  therapy  indicated  for  the
treatment of RA. MTX is an analogue of folate and,
hence, has structural and physiochemical properties
considerably  similar  to  those  of  folate;  it  has  two
carboxyl  groups  in  its  molecule  and both  of  them
are  most  completely  dissociated  in  the  physio-
logical  conditions  [52].  It  is  unable  to  cross
biological  membranes  in  the  body  by  simple
diffusion,  due  their  hydrophilicity,  suggesting
involvement of a carrier-mediated transport system.
In  this  way,  several  transporters  that  are  able  to
mediate the transport of MTX have been identified
[52].
The study of MTX started in 1948, when Sidney
Farber reports the successful use of aminopterin, an
anti-folate in the treatment of childhood leukemia.
To facilitate the manufacturing of aminopterin, the
compound was modified, leading to the synthesis of
MTX  [53].  However,  in  1950,  Phillip  Hench
received  the  Noble  Prize  for  has  study  of
corticosteroids  in  RA  and  the  clinical  community
lost the interest in the MTX treatment in RA [53].
Only  in  1962,  MTX  was  introduced  for  the
psoriatic  arthritis  therapy,  based  on  the  erroneous
supposition  of  eventual  interference  with  the
proliferation of connective tissues [45]. MTX was
only approved for RA treatment in 1988, after two
studies in which a total of 224 patient where treated
for a maximum of 24 weeks [54, 55].
The effects of MTX can be explained by several
mechanisms,  namely  (i)  inhibition  of  purine  and
pyrimidine  synthesis,  leading  to  inhibition  of
proliferation of the inflammatory synovial cells; (ii)
inhibition  of  the  synthesis  of  polyamines;  (iii)
alterations  in  cellular  redox  state  and  decrease  in
intracellular glutathione levels, resulting in reduced
macrophage  and  lymphocyte  recruitment  function
and  improved  apoptosis  sensitivity;  and  (iv)
inhibition of the enzyme aminoimidazole carboxa-
mide  ribonucleotide  (AICAR)  transformilase
(ATIC),  consequent  in  higher  AICAR  cellular
levels,  resulting  in  the  inhibition  of  AMP
deaminase  and  finally  leading  to  high  levels  of
extracellular  adenosine  [17].
Biological DMARDs
At  the  end  of  the  century,  the  RA  treatment
overview changed with the introduction of biologic
targeted therapies. These therapeutic agents include
monoclonal  antibodies  (mAbs)  and  genetically
modified proteins targeted against cytokines or cell-
surface molecules [56].  The identification of TNF
as a vital player in the inflammatory process of the
disease  constitutes  a  milestone  for  key  molecules
and cells involved in RA pathogenesis as targeted
therapies. Advances in knowledge of the role of T
cells, B cells and cytokines such as IL-1 and IL-6
have  contributed  to  the  production  of  further
biological  agents,  such  as  abatacept,  rituximab,
anakinra and tocilizumab, all  approved after  trials
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performed  against  MTX  (Table  3).  Over  the  last
years  of  experience,  bDMARDs  demonstrated  a
good  efficacy  and  safety  in  RA  patients  and  are
today  used  worldwide  in  clinical  practice  [45].
Table 3. Overview of the currently available biologic DMARDs for the treatment of RA [47, 51, 56].
Name Target Structure Mechanism Administration
Etanercept TNF Recombinant human fusion
protein of the TNF receptor and
the Fc portion of IgG1.
Works as a decoy receptor. It
binds to soluble TNF, blocking
the binding to its receptor
s.c. injection; 50mg weekly
Adalimumab TNF Fully human IgG1 mAb Binding to TNF s.c. injection; 40mg every other week
Infliximab TNF Chimeric murine-human IgG1
mAb
Binding to soluble and mb
bound TNF
i.v. infusion; for patients with RA,
dosing is 3 mg/kg at weeks 0, 2 and
6, then every 8 weeks
Golimumab TNF Fully human IgG1 mAb Binding to soluble and mb
bound TNF
s.c. injection; 50mg monthly
Certolizumab
pegol
TNF Humanized pegylated anti-TNF
Fab‘ fragment
Binding to TNF s.c. injection; 400mg initially, then
200mg every other week
Anakinra IL-1 Recombinant human IL-1
receptor antagonist
Binding to IL-1 type-1
receptor
s.c. injection once a day
Tocilizumab IL-6 Humanized recombinant IgG1
mAb
Binding to soluble and
membrane bound IL-6
receptor
i.v. infusion; in patients with RA, 8
mg/kg every 4 weeks
Rituximab B cells Chimeric murine-human IgG1
mAb
Binding to CD20 and
depletion of CD20+ B cells
Two 1000mg i.v. infusions 2 weeks
apart every 24 weeks or more
frequently depending on disease
activity
Abatacept T cells Recombinant human fusion
protein of the extracellular
domain of CTLA-4 and the Fc
portion of IgG1
Binding to CD80/CD86,
blocking T-cell co-stimulation
iv. infusion every 4 weeks or sc.
injection once a week
s.c.: subcutaneous; i.v.: intravenous; CTLA: cytotoxic T-lymphocyte-associated protein
The interest of companies in the development of
“biosimilars”  has  increased  lately,  due  to  the  fact
that  patents  for  several  biological  agents  with
expire  in  the  near  future.  Once  these  alternatives
become  cheapest,  they  could  be  translated  into  a
more cost-effective RA therapy and allow access to
biologics  for  inumerous  RA  patients  worldwide
[51].  In  September  2013,  infliximab-biosimilar
therapy  (CT-P13,  Trade  names:  Remsima  and
Inflectra) was licensed in the EU for the treatment
of  RA  [57].  Biosimilar  infliximab  products  show
similar  efficacy and safety  profiles  to  the  original
biological  agent,  and  present  similar  therapeutic
properties  to  other  TNF  inhibitors  [49].
Recommendations for the RA Treatment
In  the  last  years,  the  ACR  and  the  EULAR
published  recommendations  for  the  use  of
cDMARDs  and  bDMARDs  in  RA  treatment  [49,
58].  In  2013,  EULAR  provided  these  updated
recommendations following the same methodology
used  to  develop  the  2010  RA  recommendations
[59]. Some of the previous recommendations were
deleted,  and  others  were  edited  or  divided.  The
items intent is  to define the initiation of DMARD
treatment  using  a  csDMARD  strategy  in  combi-
nation  with  glucocorticoids,  followed  by  the
addition  of  a  bDMARD  or  another  csDMARD
strategy if any improvement is seen at 3 months, or
the treatment target is not reached within 6 months.
TNF inhibitors,  abatacept,  tocilizumab and,  under
defined  conditions,  rituximab  are  principally
considered to have comparable efficacy and safety.
If  the  first  bDMARD  agent  fails,  any  other
bDMARD may be used. The tsDMARD tofacitinib
is  also  recommended  (if  licensed),  after  use  of  at
least one bDMARD. Biosimilars are also addressed
[49].
The EULAR Task Force aimed to discriminate
some  generic  principles  of  treating  RA  from
individual  recommendations  on  individual  thera-
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peutic  approaches.  This  discussion  resulted  in  14
recommendations,  which  reflect  the  balance  of
efficacy  and  safety  of  DMARDs.  Except  for  the
first  two  items,  which  are  the  cornerstone  of  the
therapeutic approach to RA, they are not listed by
an importance order, but follow a rational sequence
and procedural hierarchy [49].
Animal Models
Animal models of several human disorders have
been  developed  with  the  aim  of  establishing
effective  and  safe  therapies.  These  experimental
models are, mostly, induced by immunization with
an antigen supposed participating in the analogous
human disease [60].
Although  several  species  have  been  used  over
the years (Table 4), rodent models of RA (both rats
and mice) are the most common. This fact is due to
the price, uniformity of the genetic background, and
in  mice,  the  ability  to  use  genetically  modified
strains.  Most  RA  animal  models  are  based  on  an
inducing agent, and even “spontaneous” models can
be  considered  induced  since  they  develop  the
disease  upon  the  addition  or  deletion  of  specific
genes  in  animals  with  a  suitable  immunologic
susceptibility  [61].
Table 4. Mouse models for RA [64].
Model type Disease name Induction agent/ target gene for manipulation
Disease
characteristics
Induced
arthritis
models
Staphylococcus aureus-induced
arthritis
Toxic shock syndrome toxin-1-producing S. aureus
LS-1 strain
Acute
Borrelia burgdorferi-associated
arthritis
Borrelia burgdorferi Acute
CIA Heterologous CII Acute/chronic
Proteoglycan-induced arthritis Human cartilage proteoglycan Acute to chronic
Pristane-induced arthritis Pristane (2,6,10,14-tetramethylpentadecane) Chronic
Anti-CII antibody-induced arthritis Transfer of CII specific antibodies Acute
Anti-GPI antibody transfer-induced
arthritis
Transfer of GPI-specific polyclonal antibodies Acute
Genetically
manipulated
models
TNF-α transgenic Human tumor necrosis factor Acute
IL-1Ra–/– IL-1 receptor antagonist Chronic
HTLV-1 env-pX transgenic HTLV-1 env-pX Chronic
K/BxN TCR transgenic KRN peptide specific TCR Chronic
HTLV: Human T-Cell Leukemia Virus; TCR: T-cell receptor; KRN: H2k restricted bovine ribonuclease
Collagen-Induced Arthritis Model
Among the aforementionated animal models for
RA,  collagen-induced  arthritis  (CIA)  in  DBA/1
mice is  the  most  commonly used.  The first  report
dates back to 1977, when Trentham and colleagues
described  that  immunization  of  rats  with  an
emulsion  of  type  II  collagen  (CII)  in  complete
Freund’s  adjuvant  (CFA)  assisted  in  the
development  of  an  erosive  polyarthritis  related  to
autoimmune response against cartilage [62]. Later,
other  researchers  have developed similar  methods
for the development of CIA in mice [63].
Several  autoimmune  disorders  include  the
manifestation  of  autoimmunity  to  autologous
proteins which have been tested for autoreactive T
cells  and  antibodies  in  both  human  disease  and
animal models. In line with this,  CII is one of the
key  autoantigens  of  human  RA  based  on  high
amounts  of  anti-CII  antibodies  and  CII-specific  T
cells  detected  in  these  patients.  This  higher
prevalence, noted particularly during the early stage
of RA, indicates that CII-specific immunity plays a
key  role  in  the  beginning  of  inflammation  in  the
articular  joints.  Since  CII  is  the  major  constituent
protein only expressed in the articular cartilage of
joints,  the  immunity  developed  against  the  CII  of
heterologous species  may induce joint  destruction
[65].  Similarly  to  RA,  CIA  mice  susceptibility  is
associated  with  the  expression  of  specific  MHC
class II molecules, specifically, I-Aq and I-Ar in the
mouse, and HLA-DR1 and -DR4 in humans [66].
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CIA  is  easily  induced  after  just  one  immuni-
zation  with  heterologous  CII.  This  process  boosts
the  immune  system  after  few  days,  followed  by
immune activation in the joints after 1-2 weeks and
an  abrupt  establishment  of  macroscopic  arthritis
just  after  2  weeks,  which  can  be  maintained  for
several  months  after  immunization.  Within  a  few
days  after  disease  establishment,  an  inflammatory
reaction  damages  the  joint,  with  a  very  similar
histopathology  as  observed  in  humans  (Table  5).
Active inflammation will decrease 3–4 weeks after
disease  establishment,  leaving  behind  a  destroyed
joint behind, but without inflammation [67].
CIA reacts  poorly  to  NSAIDs  or  MTX,  and  is
mainly  unresponsive  by  gold  salts,  chloroquine,
colchicine  or  levamisole.  The  reduced  NSAID
activity  in  CIA  is  considered  as  an  additional
advantage  over  other  arthritis  models  [68].
Table 5. Similarities and differences between human RA and CIA in DBA/1 Mice [63].
RA CIA
Similarities Polyarticular Polyarticular
Predisposition to RA is associated with certain MHC-II
haplotypes
Susceptibility to CIA is associated with certain H-2
complex
Joint pathology:
Hyperplasia of synovial membrane
Synovial immune infiltration
Neutrophils in synovial fluid
Pannus formation
Bone destruction by osteoclasts
Joint pathology:
Hyperplasia of synovial membrane
Synovial immune infiltration
Neutrophils in synovial fluid
Pannus formation
Bone destruction by osteoclasts
Serological markers:
Rheumatoid factor
Anti-CII antibodies
Anticyclic citrullinated peptide antibodies
Serological markers:
Rheumatoid factor
Anti-CII antibodies
Anticyclic citrullinated peptide antibodies
Differences Symmetric joint involvement Nonsymmetric joint involvement
Chronic Transient
Systemic/extra-articular manifestations No reports about systemic manifestations
CONCLUSION
Significant  advances  have  been  made  in  our
knowledge  about  RA  over  the  past  decades.
Valuable new information has been obtained from
epidemiologic  and  genetic  investigations,  which
has  allowed  the  identification  of  pathogenic  and
regulatory components.  Rheumatoid synovitis is a
complex  process  in  which  loss  in  self-tolerance
results  in  anomalies  including  recognition  of
citrullinated  antigens  by  B  and  T  cells.  The
identification  of  biological  markers,  allows  the
implementation of new RA classification criteria, to
include  patients  at  the  earliest  stages  of  disease,
reducing their activity, preventing joint destruction
and preserving physical function.
The discovery and targeting of  novel  pertinent
pathways in the pathogenesis of RA created a huge
opportunity of controlling this disease. It has been
highlighted  how  the  human  genetic  data  can  be
efficiently  integrated  with  other  biological
information  to  originate  biological  insights  and
drive  drug  discovery.  Indeed,  comprehensive
genetic  studies  shed  light  on  fundamental  genes,
pathways  and  cell  types  that  contribute  to  RA
pathogenesis,  and provide empirical  evidence that
the  genetics  of  RA  can  provide  important
information  about  drug  discovery,  and  personal
treatment  of  RA  patients.
Further, knowledge of the mechanisms of action
of DMARDs has contributed to the development of
more effective therapy strategies. Biologic agents,
the newer group of DMARDS, have improved the
treatment outcome of patients. However, the higher
cost is limiting their use. In this way, more efficient
strategies have to be identified in order to improve
inflammatory  disease  treatments  while  decreasing
the side effects with an improved cost-benefit ratio.
Animal  models  have  been  a  valuable  tool,
because  they  enable  the  establishment  of  more
accurate  models  to  predict  the  several  precise
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variants  of  human autoimmune diseases including
the  early  starting  phase.  In  this  way,  we  can  be
confident  that  the  near  future  will  provide  the
means  for  effective  treatment  efficiently  of  RA
patients.
LIST OF ABBREVIATIONS
ACPA = Anti-Citrullinated Peptide
ACR = American College of Rheumatology
AICAR = Aminoimidazole  Carboxamide  Ribonucleo-
tide
ATIC = AICAR Transformilase
bDMARD = Biological DNARD
bsDMARD = Biosimilars DMARD
CCP = Cyclic Citrullinated Peptide
CFA = Complete Freund’s Adjuvant
CIA = Collagen Induced Arthritis
CII = Type II Collagen
csDMARD = Conventional sDMARD
CTLA = Cytotoxic T-Lymphocyte-Associated Protein
DHFR = Dihydrofolate Reductase
DHODH = Dehydroorotate Dehydrogenase
DMARD = Disease-Modifying Antirheumatic Drug
EMA = European Medicines Agency
EULAR = European League Against Rheumatism
Fc = Fragment Crystallizable
FDA = Food and Drug Administration
HLA = Human Leukocyte Antigen
HTLV = Human T-Cell Leukemia Virus
IFN = Interferon
IgG = Imunoglobulina G
IκB = Inhibitor of Kappa B
IL = Interleukin
i.v. = Intravenous
JNK = Janus N-Terminal Kinase
KRN = H2k Restricted Bovine Ribonuclease
mAb = Monoclonal antibody
MCP = Monocyte Chemoattractant Protein
MHC = Major Histocompatibility Complex
MTX = Methotrexate
NF-κB = Factor Nuclear Kappa B
NSAID = Nonsteroidal Anti-Inflammatory Drug
PTPN = Protein Tyrosine Phosphatase Nonreceptor
RA = Rheumatoid Arthritis
RF = Rheumatic Factor
s.c. = Subcutaneous
sDMARD = Synthetic DMARD
SE = Shared Epitope
SF = Synovial Fibroblasts
STAT = Signal  Transducer  and  Activator  of
Transcription
TCR = T-Cell Receptor
Th = T Helper
TNF = Tumour Necrosis Factor
TNFAIP3 = TNF Alpha Induced Protein 3
TRAF1/C5 = TNF–Associated  Factor  1  and  Complement
Component C5
TS = Thymidilate Synthase
tsDMARD = Targeted sDMARD
TYC = Tyrosine-Protein Kinase
CONFLICT OF INTEREST
The authors confirm that this article content has
no conflict of interest.
ACKNOWLEDGEMENTS
Eugénia  Nogueira  (SFRH/BD/81269/2011)
holds a scholarship from Fundação para a Ciência e
a Tecnologia (FCT). This study was funded by the
European  Union  Seventh  Framework  Programme
(FP7/2007-2013)  under  grant  agreement  NMP4-
LA-2009-228827  NANOFOL.  The  authors  thank
the FCT Strategic Project of UID/BIO/04469/2013
unit,  the  project  RECI/BBB-EBI/0179/2012
(FCOMP-01-0124-FEDER-027462) and the Project
“BioHealth  -  Biotechnology  and  Bioengineering
approaches  to  improve  health  quality",  Ref.
NORTE-07-0124-FEDER-000027,  co-funded  by
the  Programa  Operacional  Regional  do  Norte
(ON.2  –  O  Novo  Norte),  QREN,  FEDER.  This
work was also supported by FCT I.P.  through the
strategic funding UID/BIA/04050/2013.
REFERENCES
Shrivastava, A.K.; Pandey, A. Inflammation and rheumatoid[1]
arthritis. J. Physiol. Biochem., 2013, 69(2), 335-347.
[http://dx.doi.org/10.1007/s13105-012-0216-5]  [PMID:
23385669]
Kourilovitch,  M.;  Galarza-Maldonado,  C.;  Ortiz-Prado,  E.[2]
Diagnosis  and  classification  of  rheumatoid  arthritis.  J.
Autoimmun.,  2014,  48-49,  26-30.
[http://dx.doi.org/10.1016/j.jaut.2014.01.027]  [PMID:
24568777]
Sanmartí,  R.;  Ruiz-Esquide,  V.;  Hernández,  M.V.[3]
Rheumatoid arthritis: a clinical overview of new diagnostic
and  treatment  approaches.  Curr.  Top.  Med.  Chem.,  2013,
13(6), 698-704.
12   Current Medicinal Chemistry, 2016, Vol. 23, No. 42 Nogueira et al.
[http://dx.doi.org/10.2174/15680266113139990092]  [PMID:
23574518]
Davis,  J.M.,  III;  Matteson,  E.L.  American  College  of[4]
Rheumatology; European League Against Rheumatism. My
treatment approach to rheumatoid arthritis. Mayo Clin. Proc.,
2012, 87(7), 659-673.
[http://dx.doi.org/10.1016/j.mayocp.2012.03.011]  [PMID:
22766086]
Kitas,  G.D.;  Gabriel,  S.E.  Cardiovascular  disease  in[5]
rheumatoid arthritis: state of the art and future perspectives.
Ann. Rheum. Dis., 2011, 70(1), 8-14.
[http://dx.doi.org/10.1136/ard.2010.142133]  [PMID:
21109513]
Koota, K.; Isomäki, H.; Mutru, O. Death rate and causes of[6]
death in RA patients during a period of five years. Scand. J.
Rheumatol., 1977, 6(4), 241-244.
[http://dx.doi.org/10.3109/03009747709095458]  [PMID:
607393]
Myllykangas-Luosujärvi,  R.A.;  Aho,  K.;  Isomäki,  H.A.[7]
Mortality  in  rheumatoid  arthritis.  Semin.  Arthritis  Rheum.,
1995, 25(3), 193-202.
[http://dx.doi.org/10.1016/S0049-0172(95)80031-X]  [PMID:
8650589]
Imboden,  J.B.  The  immunopathogenesis  of  rheumatoid[8]
arthritis. Annu. Rev. Pathol., 2009, 4(1), 417-434.
[http://dx.doi.org/10.1146/annurev.pathol.4.110807.092254]
[PMID: 18954286]
Willemze, A.; Toes, R.E.; Huizinga, T.W.; Trouw, L.A. New[9]
biomarkers  in  rheumatoid  arthritis.  Neth.  J.  Med.,  2012,
70(9),  392-399.
[PMID: 23123533]
Stahl, E.A.; Raychaudhuri, S.; Remmers, E.F.; Xie, G.; Eyre,[10]
S.; Thomson, B.P.; Li, Y.; Kurreeman, F.A.; Zhernakova, A.;
Hinks,  A.;  Guiducci,  C.;  Chen,  R.;  Alfredsson,  L.;  Amos,
C.I.; Ardlie, K.G.; Barton, A.; Bowes, J.; Brouwer, E.; Burtt,
N.P.; Catanese, J.J.; Coblyn, J.; Coenen, M.J.; Costenbader,
K.H.; Criswell, L.A.; Crusius, J.B.; Cui, J.; de Bakker, P.I.;
De Jager, P.L.; Ding, B.; Emery, P.; Flynn, E.; Harrison, P.;
Hocking, L.J.;  Huizinga,  T.W.; Kastner,  D.L.;  Ke, X.;  Lee,
A.T.;  Liu,  X.;  Martin,  P.;  Morgan,  A.W.;  Padyukov,  L.;
Posthumus, M.D.; Radstake, T.R.; Reid, D.M.; Seielstad, M.;
Seldin, M.F.; Shadick, N.A.; Steer, S.; Tak, P.P.; Thomson,
W.;  van der  Helm-van Mil,  A.H.;  van der  Horst-Bruinsma,
I.E.;  van der Schoot,  C.E.; van Riel,  P.L.;  Weinblatt,  M.E.;
Wilson, A.G.; Wolbink, G.J.; Wordsworth, B.P.; Wijmenga,
C.; Karlson, E.W.; Toes, R.E.; de Vries, N.; Begovich, A.B.;
Worthington,  J.;  Siminovitch,  K.A.;  Gregersen,  P.K.;
Klareskog, L.; Plenge, R.M. Genome-wide association study
meta-analysis identifies seven new rheumatoid arthritis risk
loci. Nat. Genet., 2010, 42(6), 508-514.
[http://dx.doi.org/10.1038/ng.582] [PMID: 20453842]
Okada, Y.; Wu, D.; Trynka, G.; Raj, T.; Terao, C.; Ikari, K.;[11]
Kochi,  Y.;  Ohmura,  K.;  Suzuki,  A.;  Yoshida,  S.;  Graham,
R.R.;  Manoharan,  A.;  Ortmann,  W.;  Bhangale,  T.;  Denny,
J.C.;  Carroll,  R.J.;  Eyler,  A.E.;  Greenberg,  J.D.;  Kremer,
J.M.; Pappas, D.A.; Jiang, L.; Yin, J.; Ye, L.; Su, D.F.; Yang,
J.; Xie, G.; Keystone, E.; Westra, H.J.; Esko, T.; Metspalu,
A.;  Zhou, X.;  Gupta,  N.;  Mirel,  D.;  Stahl,  E.A.;  Diogo, D.;
Cui, J.; Liao, K.; Guo, M.H.; Myouzen, K.; Kawaguchi, T.;
Coenen, M.J.; van Riel, P.L.; van de Laar, M.A.; Guchelaar,
H.J.; Huizinga, T.W.; Dieudé, P.; Mariette, X.; Bridges, S.L.,
Jr; Zhernakova, A.; Toes, R.E.; Tak, P.P.; Miceli-Richard, C.;
Bang,  S.Y.;  Lee,  H.S.;  Martin,  J.;  Gonzalez-Gay,  M.A.;
Rodriguez-Rodriguez, L.; Rantapä-Dahlqvist, S.; Arlestig, L.;
Choi, H.K.; Kamatani, Y.; Galan, P.; Lathrop, M.; Eyre, S.;
Bowes,  J.;  Barton,  A.;  de  Vries,  N.;  Moreland,  L.W.;
Criswell,  L.A.;  Karlson,  E.W.;  Taniguchi,  A.;  Yamada,  R.;
Kubo, M.;  Liu,  J.S.;  Bae,  S.C.;  Worthington,  J.;  Padyukov,
L.;  Klareskog,  L.;  Gregersen,  P.K.;  Raychaudhuri,  S.;
Stranger,  B.E.;  De  Jager,  P.L.;  Franke,  L.;  Visscher,  P.M.;
Brown, M.A.; Yamanaka, H.; Mimori, T.; Takahashi, A.; Xu,
H.;  Behrens,  T.W.;  Siminovitch,  K.A.;  Momohara,  S.;
Matsuda,  F.;  Yamamoto,  K.;  Plenge,  R.M.  Genetics  of
rheumatoid  arthritis  contributes  to  biology  and  drug
discovery.  Nature,  2014,  506(7488),  376-381.
[http://dx.doi.org/10.1038/nature12873] [PMID: 24390342]
Suzuki,  A.;  Kochi,  Y.;  Okada,  Y.;  Yamamoto,  K.  Insight[12]
from genome-wide association studies in rheumatoid arthritis
and multiple sclerosis. FEBS Lett., 2011, 585(23), 3627-3632.
[http://dx.doi.org/10.1016/j.febslet.2011.05.025]  [PMID:
21600898]
Saad,  M.N.;  Mabrouk,  M.S.;  Eldeib,  A.M.;  Shaker,  O.G.[13]
Identification  of  rheumatoid  arthritis  biomarkers  based  on
single  nucleotide  polymorphisms  and  haplotype  blocks:  A
systematic review and meta-analysis. J. Adv. Res., 2016, 7(1),
1-16.
[http://dx.doi.org/10.1016/j.jare.2015.01.008]  [PMID:
26843965]
McInnes,  I.B.;  Schett,  G.  The  pathogenesis  of  rheumatoid[14]
arthritis. N. Engl. J. Med., 2011, 365(23), 2205-2219.
[http://dx.doi.org/10.1056/NEJMra1004965]  [PMID:
22150039]
Boissier,  M.C.;  Semerano,  L.;  Challal,  S.;  Saidenberg-[15]
Kermanac’h,  N.;  Falgarone,  G.  Rheumatoid  arthritis:  from
autoimmunity  to  synovitis  and  joint  destruction.  J.
Autoimmun.,  2012,  39(3),  222-228.
[http://dx.doi.org/10.1016/j.jaut.2012.05.021]  [PMID:
22704962]
Arnett,  F.C.; Edworthy, S.M.; Bloch, D.A.; McShane, D.J.;[16]
Fries, J.F.; Cooper, N.S.; Healey, L.A.; Kaplan, S.R.; Liang,
M.H.; Luthra, H.S. The American Rheumatism Association
1987  revised  criteria  for  the  classification  of  rheumatoid
arthritis. Arthritis Rheum., 1988, 31(3), 315-324.
[http://dx.doi.org/10.1002/art.1780310302] [PMID: 3358796]
Colmegna,  I.;  Ohata,  B.R.;  Menard,  H.A.  Current[17]
understanding  of  rheumatoid  arthritis  therapy.  Clin.
Pharmacol.  Ther.,  2012,  91(4),  607-620.
[http://dx.doi.org/10.1038/clpt.2011.325] [PMID: 22357455]
Deane, K.D. Preclinical rheumatoid arthritis (autoantibodies):[18]
an updated review. Cur. Rheumatol. Rep., 2014, 16(5), 14-41.
Aletaha,  D.;  Neogi,  T.;  Silman,  A.J.;  Funovits,  J.;  Felson,[19]
D.T.; Bingham, C.O., III; Birnbaum, N.S.; Burmester, G.R.;
Bykerk, V.P.; Cohen, M.D.; Combe, B.; Costenbader, K.H.;
Dougados,  M.;  Emery,  P.;  Ferraccioli,  G.;  Hazes,  J.M.;
Hobbs, K.; Huizinga, T.W.; Kavanaugh, A.; Kay, J.; Kvien,
T.K.; Laing, T.; Mease, P.; Ménard, H.A.; Moreland, L.W.;
Naden, R.L.; Pincus, T.; Smolen, J.S.; Stanislawska-Biernat,
E.; Symmons, D.; Tak, P.P.; Upchurch, K.S.; Vencovský, J.;
Wolfe,  F.;  Hawker,  G.  2010  Rheumatoid  arthritis
classification  criteria:  an  American  College  of
Rheumatology/European  League  Against  Rheumatism
collaborative  initiative.  Arthritis  Rheum.,  2010,  62(9),
2569-2581.
[http://dx.doi.org/10.1002/art.27584] [PMID: 20872595]
Kay,  J.;  Upchurch,  K.S.  ACR/EULAR  2010  rheumatoid[20]
arthritis classification criteria. Rheumatology (Oxford), 2012,
51(Suppl. 6), vi5-vi9.
[http://dx.doi.org/10.1093/rheumatology/kes279]  [PMID:
23221588]
Holmdahl,  R.;  Malmström,  V.;  Burkhardt,  H.  Autoimmune[21]
priming,  tissue  attack  and chronic  inflammation -  the  three
stages of rheumatoid arthritis. Eur. J. Immunol., 2014, 44(6),
1593-1599.
[http://dx.doi.org/10.1002/eji.201444486] [PMID: 24737176]
Update on Therapeutic Approaches for Rheumatoid Arthritis Current Medicinal Chemistry, 2016, Vol. 23, No. 42   13
Smolen,  J.S.;  Steiner,  G.  Therapeutic  strategies  for[22]
rheumatoid  arthritis.  Nat.  Rev.  Drug  Discov.,  2003,  2(6),
473-488.
[http://dx.doi.org/10.1038/nrd1109] [PMID: 12776222]
Choy, E. Understanding the dynamics: pathways involved in[23]
the  pathogenesis  of  rheumatoid  arthritis.  Rheumatology
(Oxford),  2012,  51(51)(Suppl.  5),  v3-v11.
[http://dx.doi.org/10.1093/rheumatology/kes113]  [PMID:
22718924]
Alunno,  A.;  Manetti,  M.;  Caterbi,  S.;  Ibba-Manneschi,  L.;[24]
Bistoni, O.; Bartoloni, E.; Valentini, V.; Terenzi, R.; Gerli, R.
Altered immunoregulation in rheumatoid arthritis: the role of
regulatory  T  cells  and  proinflammatory  Th17  cells  and
therapeutic  implications.  Mediators  Inflamm.,  2015,  2015,
751793.
[http://dx.doi.org/10.1155/2015/751793] [PMID: 25918479]
Noack, M.; Miossec, P. Th17 and regulatory T cell balance in[25]
autoimmune  and  inflammatory  diseases.  Autoimmun.  Rev.,
2014, 13(6), 668-677.
[http://dx.doi.org/10.1016/j.autrev.2013.12.004]  [PMID:
24418308]
Son,  H.J.;  Lee,  J.;  Lee,  S.Y.;  Kim,  E.K.;  Park,  M.J.;  Kim,[26]
K.W.;  Park,  S.H.;  Cho,  M.L.  Metformin  attenuates
experimental  autoimmune  arthritis  through  reciprocal
regulation  of  Th17/Treg  balance  and  osteoclastogenesis.
Mediators  Inflamm.,  2014,  2014(10),  973986.
[PMID: 25214721]
Trifari, S.; Kaplan, C.D.; Tran, E.H.; Crellin, N.K.; Spits, H.[27]
Identification  of  a  human helper  T  cell  population  that  has
abundant  production  of  interleukin  22  and  is  distinct  from
T(H)-17, T(H)1 and T(H)2 cells. Nat. Immunol., 2009, 10(8),
864-871.
[http://dx.doi.org/10.1038/ni.1770] [PMID: 19578368]
Zhang, L.; Li, Y.G.; Li, Y.H.; Qi, L.; Liu, X.G.; Yuan, C.Z.;[28]
Hu,  N.W.;  Ma,  D.X.;  Li,  Z.F.;  Yang,  Q.;  Li,  W.;  Li,  J.M.
Increased frequencies of Th22 cells as well as Th17 cells in
the peripheral blood of patients with ankylosing spondylitis
and rheumatoid arthritis. PLoS One, 2012, 7(4), e31000.
[http://dx.doi.org/10.1371/journal.pone.0031000]  [PMID:
22485125]
Zhang, L.; Li, J.M.; Liu, X.G.; Ma, D.X.; Hu, N.W.; Li, Y.G.;[29]
Li,  W.;  Hu,  Y.;  Yu,  S.;  Qu,  X.;  Yang,  M.X.;  Feng,  A.L.;
Wang, G.H. Elevated Th22 cells correlated with Th17 cells in
patients  with  rheumatoid  arthritis.  J.  Clin.  Immunol.,  2011,
31(4), 606-614.
[http://dx.doi.org/10.1007/s10875-011-9540-8]  [PMID:
21556937]
van Hamburg, J.P.; Corneth, O.B.; Paulissen, S.M.; Davelaar,[30]
N.; Asmawidjaja, P.S.; Lubberts, E. Th17 but not Th22 cells
display pathological behaviour in arthritis. Ann. Rheum. Dis.,
2012, 71(Suppl. 1), A89.
[http://dx.doi.org/10.1136/annrheumdis-2011-201239.9]
Talotta,  R.;  Berzi,  A.M.;  Atzeni,  F.;  Dell'Acqua,  D.;[31]
Trabattoni,  D.;  Sarzi-Puttini,  P.  AB0429 The  Role  of  TH9
Lymphocytes  in  Rheumatoid  Arthritis.  Ann.  Rheum.  Dis.,
2015, 74(Suppl. 2), 1037-1038.
[http://dx.doi.org/10.1136/annrheumdis-2015-eular.2791]
[PMID: 24550168]
Ciccia, F.; Guggino, G.; Rizzo, A.; Manzo, A.; Vitolo, B.; La[32]
Manna, M.P.; Giardina, G.; Sireci, G.; Dieli, F.; Montecucco,
C.M.;  Alessandro,  R.;  Triolo,  G.  Potential  involvement  of
IL-9 and Th9 cells in the pathogenesis of rheumatoid arthritis.
Rheumatology (Oxford), 2015, 54(12), 2264-2272.
[http://dx.doi.org/10.1093/rheumatology/kev252]  [PMID:
26178600]
Nogueira,  E.;  Gomes,  A.C.;  Preto,  A.;  Cavaco-Paulo,  A.[33]
Folate-targeted nanoparticles for rheumatoid arthritis therapy.
Nanomed. Nanotechnol. Biol. Med., 2016, 12(4), 1113-26.
Kim, H-J; Berek, C. B cells in rheumatoid arthritis. Arthritis[34]
Research & Therapy, 2000, 2(2), 126-31.
[http://dx.doi.org/10.1186/ar77]
Wang, Q.; Ma, Y.; Liu, D.; Zhang, L.; Wei, W. The roles of B[35]
cells and their interactions with fibroblast-like synoviocytes
in the pathogenesis of rheumatoid arthritis. Int. Arch. Allergy
Immunol., 2011, 155(3), 205-211.
[http://dx.doi.org/10.1159/000321185] [PMID: 21293141]
Lefèvre, S.; Knedla, A.; Tennie, C.; Kampmann, A.; Wunrau,[36]
C.;  Dinser,  R.;  Korb,  A.;  Schnäker,  E.M.;  Tarner,  I.H.;
Robbins, P.D.; Evans, C.H.; Stürz, H.; Steinmeyer, J.; Gay,
S.; Schölmerich, J.; Pap, T.; Müller-Ladner, U.; Neumann, E.
Synovial fibroblasts spread rheumatoid arthritis to unaffected
joints. Nat. Med., 2009, 15(12), 1414-1420.
[http://dx.doi.org/10.1038/nm.2050] [PMID: 19898488]
Huber, L.C.; Distler, O.; Tarner, I.; Gay, R.E.; Gay, S.; Pap,[37]
T. Synovial fibroblasts: key players in rheumatoid arthritis.
Rheumatology (Oxford), 2006, 45(6), 669-675.
[http://dx.doi.org/10.1093/rheumatology/kel065]  [PMID:
16567358]
Schett,  G.  Cells  of  the  synovium  in  rheumatoid  arthritis.[38]
Osteoclasts. Arthritis Res. Ther., 2007, 9(1), 203.
[http://dx.doi.org/10.1186/ar2110] [PMID: 17316459]
Shaw,  AT;  Gravallese,  EM Mediators  of  inflammation  and[39]
bone remodeling in rheumatic disease. Semin. Cell Dev. Biol.,
2016, 49, 2-10.
[http://dx.doi.org/10.1016/j.semcdb.2015.10.013]
Otero,  M.;  Goldring,  M.B.  Cells  of  the  synovium  in[40]
rheumatoid arthritis. Chondrocytes. Arthritis Res. Ther., 2007,
9(5), 220.
[http://dx.doi.org/10.1186/ar2292] [PMID: 18001488]
Baschant, U.; Lane, N.E.; Tuckermann, J. The multiple facets[41]
of  glucocorticoid  action  in  rheumatoid  arthritis.  Nat.  Rev.
Rheumatol., 2012, 8(11), 645-655.
[http://dx.doi.org/10.1038/nrrheum.2012.166]  [PMID:
23045254]
Maruotti,  N.;  Annese,  T.;  Cantatore,  F.P.;  Ribatti,  D.[42]
Macrophages and angiogenesis in rheumatic diseases. Vasc.
Cell, 2013, 5(1), 11.
[http://dx.doi.org/10.1186/2045-824X-5-11]  [PMID:
23725043]
Xia,  W.;  Hilgenbrink,  A.R.;  Matteson,  E.L.;  Lockwood,[43]
M.B.; Cheng, J.X.; Low, P.S. A functional folate receptor is
induced  during  macrophage  activation  and  can  be  used  to
target drugs to activated macrophages. Blood, 2009, 113(2),
438-446.
[http://dx.doi.org/10.1182/blood-2008-04-150789]  [PMID:
18952896]
Paulos,  C.M.;  Turk,  M.J.;  Breur,  G.J.;  Low,  P.S.  Folate[44]
receptor-mediated targeting of therapeutic and imaging agents
to activated macrophages in rheumatoid arthritis. Adv. Drug
Deliv. Rev., 2004, 56(8), 1205-1217.
[http://dx.doi.org/10.1016/j.addr.2004.01.012]  [PMID:
15094216]
Favalli, E.G.; Biggioggero, M.; Meroni, P.L. Methotrexate for[45]
the treatment of rheumatoid arthritis in the biologic era: still
an  “anchor”  drug?  Autoimmun.  Rev.,  2014,  13(11),
1102-1108.
[http://dx.doi.org/10.1016/j.autrev.2014.08.026]  [PMID:
25172238]
Demoruelle, M.K.; Deane, K.D. Treatment strategies in early[46]
rheumatoid  arthritis  and  prevention  of  rheumatoid  arthritis.
Curr. Rheumatol. Rep., 2012, 14(5), 472-480.
[http://dx.doi.org/10.1007/s11926-012-0275-1]  [PMID:
22773387]
Meier,  F.M.;  Frerix,  M.;  Hermann,  W.;  Müller-Ladner,  U.[47]
14   Current Medicinal Chemistry, 2016, Vol. 23, No. 42 Nogueira et al.
Current  immunotherapy  in  rheumatoid  arthritis.  Immuno-
therapy,  2013,  5(9),  955-974.
[http://dx.doi.org/10.2217/imt.13.94] [PMID: 23998731]
Smolen, J.S.; van der Heijde, D.; Machold, K.P.; Aletaha, D.;[48]
Landewé,  R.  Proposal  for  a  new  nomenclature  of  disease-
modifying  antirheumatic  drugs.  Ann.  Rheum.  Dis.,  2014,
73(1),  3-5.
[http://dx.doi.org/10.1136/annrheumdis-2013-204317]
[PMID: 24072562]
Smolen,  J.S.;  Landewé,  R.;  Breedveld,  F.C.  EULAR[49]
recommendations for the management of rheumatoid arthritis
with  synthetic  and  biological  disease-modifying
antirheumatic drugs: 2013 update. Ann. Rheum. Dis., 2013.
[PMID: 24161836]
Scher, J.U. Monotherapy in rheumatoid arthritis. Bull. Hosp.[50]
Jt. Dis., 2013, 71(3), 204-207.
[PMID: 24151946]
Vivar, N.; Van Vollenhoven, R.F. Advances in the treatment[51]
of rheumatoid arthritis. F1000Prime Rep., 2014, 6, 31.
[http://dx.doi.org/10.12703/P6-31] [PMID: 24860653]
Inoue,  K.;  Yuasa,  H.  Molecular  basis  for  pharmacokinetics[52]
and  pharmacodynamics  of  methotrexate  in  rheumatoid
arthritis therapy. Drug Metab. Pharmacokinet., 2014, 29(1),
12-19.
[http://dx.doi.org/10.2133/dmpk.DMPK-13-RV-119]  [PMID:
24284432]
Weinblatt,  M.E.  Methotrexate  in  rheumatoid  arthritis:  a[53]
quarter century of development. Trans. Am. Clin. Climatol.
Assoc., 2013, 124, 16-25.
[PMID: 23874006]
Weinblatt,  M.E.;  Coblyn,  J.S.;  Fox,  D.A.;  Fraser,  P.A.;[54]
Holdsworth,  D.E.;  Glass,  D.N.;  Trentham, D.E. Efficacy of
low-dose  methotrexate  in  rheumatoid  arthritis.  N.  Engl.  J.
Med., 1985, 312(13), 818-822.
[http://dx.doi.org/10.1056/NEJM198503283121303]  [PMID:
3883172]
Williams, H.J.; Willkens, R.F.; Samuelson, C.O., Jr; Alarcón,[55]
G.S.; Guttadauria, M.; Yarboro, C.; Polisson, R.P.; Weiner,
S.R.;  Luggen,  M.E.;  Billingsley,  L.M.  Comparison  of  low-
dose oral pulse methotrexate and placebo in the treatment of
rheumatoid  arthritis.  A  controlled  clinical  trial.  Arthritis
Rheum.,  1985,  28(7),  721-730.
[http://dx.doi.org/10.1002/art.1780280702] [PMID: 3893441]
Upchurch,  K.S.;  Kay,  J.  Evolution  of  treatment  for[56]
rheumatoid  arthritis.  Rheumatology  (Oxford),  2012,
51(6)(Suppl.  6),  vi28-vi36.
[PMID: 23221584]
Baji,  P.;  Péntek,  M.;  Czirják,  L.;  Szekanecz,  Z.;  Nagy,  G.;[57]
Gulácsi, L.; Brodszky, V. Efficacy and safety of infliximab-
biosimilar compared to other biological drugs in rheumatoid
arthritis: a mixed treatment comparison. Eur. J. Health Econ.,
2014, 15(Suppl. 1), S53-S64.
[http://dx.doi.org/10.1007/s10198-014-0594-4]  [PMID:
24832836]
Singh, J.A.; Furst, D.E.; Bharat, A.; Curtis, J.R.; Kavanaugh,[58]
A.F.;  Kremer,  J.M.;  Moreland,  L.W.;  O’Dell,  J.;  Winthrop,
K.L.;  Beukelman,  T.;  Bridges,  S.L.,  Jr;  Chatham,  W.W.;
Paulus,  H.E.;  Suarez-Almazor,  M.;  Bombardier,  C.;
Dougados,  M.;  Khanna,  D.;  King,  C.M.;  Leong,  A.L.;
Matteson, E.L.; Schousboe, J.T.; Moynihan, E.; Kolba, K.S.;
Jain,  A.;  Volkmann,  E.R.;  Agrawal,  H.;  Bae,  S.;  Mudano,
A.S.;  Patkar,  N.M.;  Saag,  K.G.  2012  update  of  the  2008
American College of Rheumatology recommendations for the
use  of  disease-modifying  antirheumatic  drugs  and  biologic
agents in the treatment of rheumatoid arthritis. Arthritis Care
Res. (Hoboken), 2012, 64(5), 625-639.
[http://dx.doi.org/10.1002/acr.21641] [PMID: 22473917]
Smolen, J.S.; Landewé, R.; Breedveld, F.C.; Dougados, M.;[59]
Emery, P.; Gaujoux-Viala, C.; Gorter, S.; Knevel, R.; Nam,
J.; Schoels, M.; Aletaha, D.; Buch, M.; Gossec, L.; Huizinga,
T.;  Bijlsma,  J.W.;  Burmester,  G.;  Combe,  B.;  Cutolo,  M.;
Gabay,  C.;  Gomez-Reino,  J.;  Kouloumas,  M.;  Kvien,  T.K.;
Martin-Mola,  E.;  McInnes,  I.;  Pavelka,  K.;  van  Riel,  P.;
Scholte,  M.;  Scott,  D.L.;  Sokka,  T.;  Valesini,  G.;  van
Vollenhoven, R.; Winthrop, K.L.; Wong, J.; Zink, A.; van der
Heijde, D. EULAR recommendations for the management of
rheumatoid  arthritis  with  synthetic  and  biological  disease-
modifying  antirheumatic  drugs.  Ann.  Rheum.  Dis.,  2010,
69(6),  964-975.
[http://dx.doi.org/10.1136/ard.2009.126532]  [PMID:
20444750]
Myers,  L.K.;  Rosloniec,  E.F.;  Cremer,  M.A.;  Kang,  A.H.[60]
Collagen-induced arthritis, an animal model of autoimmunity.
Life Sci., 1997, 61(19), 1861-1878.
[http://dx.doi.org/10.1016/S0024-3205(97)00480-3]  [PMID:
9364191]
Kannan,  K.;  Ortmann,  R.A.;  Kimpel,  D.  Animal  models  of[61]
rheumatoid  arthritis  and  their  relevance  to  human  disease.
Pathophysiology, 2005, 12(3), 167-181.
[http://dx.doi.org/10.1016/j.pathophys.2005.07.011]  [PMID:
16171986]
Trentham, D.E.; Townes, A.S.; Kang, A.H. Autoimmunity to[62]
type II  collagen an experimental  model  of  arthritis.  J.  Exp.
Med., 1977, 146(3), 857-868.
[http://dx.doi.org/10.1084/jem.146.3.857] [PMID: 894190]
Schurgers,  E.;  Billiau,  A.;  Matthys,  P.  Collagen-induced[63]
arthritis as an animal model for rheumatoid arthritis: focus on
interferon-γ.  J.  Interferon  Cytokine  Res.,  2011,  31(12),
917-926.
[http://dx.doi.org/10.1089/jir.2011.0056] [PMID: 21905879]
Lindqvist,  A-K.;  Bockermann,  R.;  Johansson,  Å.C.;[64]
Nandakumar,  K.S.;  Johannesson,  M.;  Holmdahl,  R.  Mouse
models for rheumatoid arthritis. Trends Genet., 2002, 18(6),
S7-S13.
[http://dx.doi.org/10.1016/S0168-9525(02)02684-7]
Cho, Y.G.; Cho, M.L.; Min, S.Y.; Kim, H.Y. Type II collagen[65]
autoimmunity  in  a  mouse  model  of  human  rheumatoid
arthritis.  Autoimmun.  Rev.,  2007,  7(1),  65-70.
[http://dx.doi.org/10.1016/j.autrev.2007.08.001]  [PMID:
17967728]
Hegen,  M.;  Keith,  J.C.,  Jr;  Collins,  M.;  Nickerson-Nutter,[66]
C.L. Utility of animal models for identification of potential
therapeutics for rheumatoid arthritis. Ann. Rheum. Dis., 2008,
67(11), 1505-1515.
[http://dx.doi.org/10.1136/ard.2007.076430]  [PMID:
18055474]
Holmdahl,  R.;  Bockermann,  R.;  Bäcklund,  J.;  Yamada,  H.[67]
The molecular pathogenesis of collagen-induced arthritis in
mice--a  model  for  rheumatoid  arthritis.  Ageing  Res.  Rev.,
2002, 1(1), 135-147.
[http://dx.doi.org/10.1016/S0047-6374(01)00371-2]  [PMID:
12039453]
Wooley,  P.H.  The  usefulness  and  the  limitations  of  animal[68]
models  in  identifying  targets  for  therapy  in  arthritis.  Best
Pract. Res. Clin. Rheumatol., 2004, 18(1), 47-58.
[http://dx.doi.org/10.1016/j.berh.2003.09.007]  [PMID:
15123037]
